RNTXHealthcare · BiotechnologyRNTX Stock Forecast: Rein Therapeutics, Inc. Price Predictions for 2026-2027
The 2 Wall Street analysts covering Rein Therapeutics, Inc. hold a median 12-month price target of $6 — +704.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 1 Aug 2026 — in the lower half.
RNTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Rein Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (88): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Rein Therapeutics, Inc. — and when they’d sell — is the membership.
RNTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RNTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +704.8% from it.
Of the 18 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 July 2026 | Maxim Group | Initiates | Buy | $4.00 |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $8.00 |
| 1 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Jan 2026 | Brookline Capital | Downgrade | Hold | — |
| 22 Sept 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 19 Aug 2025 | Brookline Capital | Downgrade | Hold | — |
| 18 Apr 2024 | Ladenburg Thalmann | Maintains | Buy | $9.00 → $19 |
| 1 Dec 2023 | Ladenburg Thalmann | Upgrade | Buy | $9.00 |
| 30 June 2022 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $1.00 |
| 29 June 2022 | William Blair | Downgrade | Market Perform | — |
| 5 June 2020 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $2.00 |
| 31 Mar 2020 | H.C. Wainwright | Maintains | Buy | — |
| 31 Mar 2020 | HC Wainwright & Co. | Maintains | Buy | $6.00 → $3.00 |
| 9 Apr 2019 | Canaccord Genuity | Maintains | Buy | $19 → $5.00 |
| 11 Mar 2019 | H.C. Wainwright | Initiates | Buy | — |
| 24 July 2017 | Bank of America | Initiates | Buy | — |
| 24 July 2017 | Canaccord Genuity | Initiates | Buy | — |
| 24 July 2017 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RNTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Rein Therapeutics, Inc. (RNTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.4×
- Price / sales
- —
- Price / book
- −0.7×
- EV / EBITDA
- −5.0×
Cheaper than 79% of US stocks
Cheaper than 94% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −163.4%
- Return on assets
- −32.1%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RNTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNTX appears on the weeks it earns a place.
Frequently asked questions about RNTX stock
What is the RNTX stock price forecast for 2026-2027?
The 2 Wall Street analysts covering Rein Therapeutics, Inc. have a median 12-month price target of $6, with estimates ranging from $4 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RNTX stock a buy right now?
Of the 2 analysts covering Rein Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rein Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RNTX?
As at 1 Aug 2026, Rein Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (88 of 100).
Will RNTX stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts implies +704.8% from the last close, and Ticker Nerd's factor model ranks Rein Therapeutics, Inc. 44 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RNTX stock forecast for 2030?
No analyst covering Rein Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $8 over the next 12 months.
How has RNTX stock performed over the past year?
Rein Therapeutics, Inc. returned -32.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rein Therapeutics, Inc. do?
Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases.
About Rein Therapeutics, Inc.
Rein Therapeutics Inc. is a biotechnology company dedicated to developing novel therapies for life-threatening diseases. The primary focus of the company lies in exploring advanced gene editing technologies to create treatments that address unmet clinical needs. Rein Therapeutics Inc. is heavily involved in research and development efforts, often collaborating with leading institutions and pharmaceutical firms to drive innovation in the biotech sector. Its groundbreaking work impacts various fields, particularly in genetic disorders, oncology, and infectious diseases. With headquarters based in a prominent biotech hub, Rein Therapeutics Inc. plays a significant role in the advancement of personalized medicine, delivering potentially transformative therapies to the market. As a publicly traded company, it attracts attention from a diverse range of investors and stakeholders interested in cutting-edge healthcare solutions.
CEO Dr. James Brian Windsor Ph.D. · 10 employees · United States · https://www.reintx.com